Formulation and specifications: Injection: 50 mg (10 ml)/vialIndications: This product is used in combination with navulizumab in adult patients with non-surgically resectable, primary non-epithelial malignant pleural mesothelioma.Rational dosing points:1. The…
Formulation and specifications: Injection: 100mg (10ml)/bottleIndications:1. Sindilizumab in combination with pemetrexed and platinum-based chemotherapy for the treatment of EGFR mutation-negative and ALK-negative advanced or recurrent non-squamous cell NSCLC without systemic…
Formulation and specifications: Injection: 100mg (10ml)/bottleIndications:1. tirelizumab in combination with paclitaxel and carboplatin or albumin paclitaxel and carboplatin for the first-line treatment of locally advanced or metastatic squamous NSCLC.2. tirelizumab…
Formulation and Specifications: Powder injection: 200 mg/vialIndications: Carrilizumab in combination with pemetrexed and carboplatin is indicated for the first-line treatment of EGFR mutation-negative and ALK-negative, non-surgically resectable locally advanced or…
Formulation and specifications: Injection: 1200mg (20ml)/bottleIndications:1. Atelelizumab is used in combination with carboplatin and etoposide for the first-line treatment of patients with ES-SCLC.2. Atelizumab is used for first-line monotherapy of…
Formulation and specifications: Injection: 120mg (2.4ml)/bottle, 500mg (10ml)/bottleIndications:.1. Duvacizumab is indicated for the treatment of unresectable, stage III NSCLC patients who have not experienced disease progression after receiving simultaneous platinum-based…
Formulation and specifications: Injection: 100mg (4ml)/bottleIndications:1. Pabrolizumab in combination with pemetrexed and platinum-based chemotherapeutic agents is indicated for the first-line treatment of EGFR mutation-negative and ALK-negative metastatic non-squamous NSCLC.2. Pabrolizumab…
Formulation and specifications: Injection: 40mg (4ml)/bottle, 100mg (10ml)/bottleIndications.1. This product alone is indicated for the treatment of adult patients with EGFR mutation-negative and ALK-negative locally advanced or metastatic NSCLC whose…
Formulation and specifications: Tablets: 100 mg, 200 mgIndications: Sevotinib is used in adult patients with locally advanced or metastatic NSCLC with exon 14 jump mutations in mesenchymal-epithelial transforming factor (MET)…
Formulation and Specifications: Capsules: 100 mgIndications: Treatment of adult patients with locally advanced or metastatic NSCLC who have received prior platinum-containing chemotherapy with a positive transfection rearrangement (RET) gene fusion.Key…